The immunoassay revolution
The field of medicine is evolving and so does the technology that supports it. One of the most significant advancements in recent years has been the automation of immunoassays. Automation has revolutionized the immunoassay landscape over the years by improving the turnaround time, accuracy, and reproducibility of immunoassay tests. The entire immunoassay procedure prior to automation involved numerous manual steps, including handling samples, preparing reagents, incubating, washing, and detecting. These manually operated procedures were time-consuming and prone to human error, leading to variability in results and limiting the throughput of clinical laboratories.
However, the introduction of automated immunoassay systems have allowed the simultaneous processing of multiple samples, minimizing hands-on time, operators errors and variations, resulting in increased accuracy and reproducibility of results. Automation has also led to the standardization of immunoassay procedures, making results more comparable between laboratories, reducing the likelihood of discrepancies.
Automated systems have also increased the range of analytes that can be detected in immunoassay procedures. The development of highly sensitive technologies such as ELFA allows for the detection of very low levels of analytes, unlocking the possibility to detect biomarkers where small amounts of analytes are present in the sample. This led to bioMérieux’s development of VIDAS® systems back in 1992. Launched over 30 years ago and adding many novel parameters along the way, VIDAS® has transformed immunoassay testing offering laboratories universal access to a simple, automated and robust technology across the continuum of both developing and developed markets, providing fast and reliable results. Featuring a single-test concept in an all-in-one kit, VIDAS® is currently used in more than 160 countries by 30,000 laboratories with many years of clinical use and validation. It is still one of the most widely used immunoassay system in clinical laboratories worldwide.
VIDAS® KUBE™, the latest addition to this innovative range, combines advanced technology with the recognized values of the VIDAS® solution. Compatible with the existing broad routine test menu covering emergency and critical care, immunochemistry and infectious diseases, the new VIDAS® KUBE™ features stackable and modular benchtop design and easy implementation that will benefit clinical diagnostic labs.
Advancements in ELFA technology are also expected to continue, with new developments in areas such as multiplexing and miniaturization.
Multiplexing enables the simultaneous testing of multiple analytes in a single sample, while miniaturization allows for testing in smaller sample volumes. The development of multiplexing and miniaturization in ELFA technology has the potential to further increase the efficiency, accuracy, and cost-effectiveness of immunoassay testing. These advancements are expected to continue to play an important role in the evolution of immunoassay technology and in meeting the evolving needs of healthcare professionals and patients.
The future of automation in the immunoassay market looks promising, and ELFA technology is expected to play a key role in driving this growth. As clinical laboratories seek to improve their testing processes, ELFA will continue to be a valuable tool in meeting the evolving needs of healthcare professionals and patients.
bioMérieux with an expertise of more than 60 years, will continue to innovate and develop cutting edge solutions with a goal to improve patient and public health. The company’s commitment to innovation and quality has enabled the company to develop a wide range of products that have addressed the needs of healthcare professionals across the globe. These solutions have helped to improve the speed and accuracy of clinical diagnoses, reduce healthcare costs, and improve patient outcomes and the future looks even more promising than ever.